Cardiovascular disorders are mainly responsible for the increased morbidity and mortality in people suffering with diabetes. The wide range of therapeutic strategies from pharmacologic treatment to antioxidant and nutritional interventions are being used to treat diabetes linked cardiovascular complications. The aim of present study was to elucidate the therapeutic role of miRNAs and Endothelin, a potent vasoconstrictor peptide in Bisphenol A induced oxidative stress generated hyperglycemia linked cardiovascular complications. Different bioinformatics tools, Targetscan, miRanda and target site analysis of different genes showed the Endothelin, as target of miRNA-1-3p, 206, 613 and 203a-3p. In addition the PKC-δ was found to be the target of miRNA-214-3p. To the best of our knowledge very few data is available about the role of miRNA-214-3p in hyperglycemia linked cardiac complications. Therefore, the in-vivo hyperglycemia linked cardiovascular disease model was established by administration of 100ug/kgBW of Bisphenol A, a well-known endocrine disruptor to Sprague Dawley rats of average age (6-7 weeks). The BPA treatment group showed increased blood glucose, body weight, cell surface area and altered cardiac tissue histology. qRT-PCR analysis showed the downregulation of miRNA-214 while upregulation of PKC-δ, and p53 in heart tissues of BPA treated model. Immunoblotting has shown that BPA increased the expression of p53. In addition, BPA administered group depicted increased reactive oxygen species and decreased antioxidant enzymes. Our findings depict the miRNA-214-3p as a new theragnostic marker for BPA induced hyperglycemia linked cardiovascular complications. However, further studies on other miRNAs are still needed to develop a cost effective therapeutic strategy for cardiovascular complications.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Metabolism - Clinical and Experimental
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect